Case Report: Safety and Efficacy of Omalizumab in a 13-Year-Old Patient With Chronic Spontaneous Urticaria and Type 1 Diabetes
Chronic urticaria (CU) is defined by the presence of itchy wheals, sometimes accompanied by angioedema, lasting for at least 6 weeks. CU is treated with second-generation antihistamines, increased up to four times the normal doses for second-line treatment. Omalizumab (a monoclonal antibody anti-IgE...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-04-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.853561/full |
| _version_ | 1818914894767980544 |
|---|---|
| author | Paolo Del Barba Federica Del Tedesco Federica Del Tedesco Giulio Frontino Giulio Frontino Maria Pia Guarneri Riccardo Bonfanti Riccardo Bonfanti Riccardo Bonfanti Graziano Barera |
| author_facet | Paolo Del Barba Federica Del Tedesco Federica Del Tedesco Giulio Frontino Giulio Frontino Maria Pia Guarneri Riccardo Bonfanti Riccardo Bonfanti Riccardo Bonfanti Graziano Barera |
| author_sort | Paolo Del Barba |
| collection | DOAJ |
| description | Chronic urticaria (CU) is defined by the presence of itchy wheals, sometimes accompanied by angioedema, lasting for at least 6 weeks. CU is treated with second-generation antihistamines, increased up to four times the normal doses for second-line treatment. Omalizumab (a monoclonal antibody anti-IgE) may be recommended as third-line therapy in children aged over 12 years. Few reports have suggested that glucose homeostasis is impaired in some type 2 diabetic patients receiving omalizumab, and even in non-diabetic patients, fasting blood glucose and HOMA-IR values appeared to be significantly increased. We report the case of a 13-year-old girl with diabetes mellitus type 1 and chronic spontaneous urticaria (CSU) refractory to standard recommended therapy that we treated with omalizumab at a standard recommended dose of 300 mg every 4 weeks. We observed a rapid and complete remission of CSU after treatment with this humanized monoclonal antibody without detrimental effects on the patient’s glucose control especially in terms of HbA1c (glycated hemoglobin), time in glycemic range (TIR), and daily insulin needs. |
| first_indexed | 2024-12-19T23:53:38Z |
| format | Article |
| id | doaj.art-a9f7dd898e0941609659796cc46483a2 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-19T23:53:38Z |
| publishDate | 2022-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-a9f7dd898e0941609659796cc46483a22022-12-21T20:01:05ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-04-011310.3389/fimmu.2022.853561853561Case Report: Safety and Efficacy of Omalizumab in a 13-Year-Old Patient With Chronic Spontaneous Urticaria and Type 1 DiabetesPaolo Del Barba0Federica Del Tedesco1Federica Del Tedesco2Giulio Frontino3Giulio Frontino4Maria Pia Guarneri5Riccardo Bonfanti6Riccardo Bonfanti7Riccardo Bonfanti8Graziano Barera9Department of Pediatrics, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milano, ItalyDepartment of Pediatrics, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milano, ItalySchool of Medicine, Università Vita Salute San Raffaele, Milano, ItalyDepartment of Pediatrics, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milano, ItalyDiabetes Research Institute, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Hospital, Milano, ItalyDepartment of Pediatrics, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milano, ItalyDepartment of Pediatrics, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milano, ItalySchool of Medicine, Università Vita Salute San Raffaele, Milano, ItalyDiabetes Research Institute, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Hospital, Milano, ItalyDepartment of Pediatrics, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milano, ItalyChronic urticaria (CU) is defined by the presence of itchy wheals, sometimes accompanied by angioedema, lasting for at least 6 weeks. CU is treated with second-generation antihistamines, increased up to four times the normal doses for second-line treatment. Omalizumab (a monoclonal antibody anti-IgE) may be recommended as third-line therapy in children aged over 12 years. Few reports have suggested that glucose homeostasis is impaired in some type 2 diabetic patients receiving omalizumab, and even in non-diabetic patients, fasting blood glucose and HOMA-IR values appeared to be significantly increased. We report the case of a 13-year-old girl with diabetes mellitus type 1 and chronic spontaneous urticaria (CSU) refractory to standard recommended therapy that we treated with omalizumab at a standard recommended dose of 300 mg every 4 weeks. We observed a rapid and complete remission of CSU after treatment with this humanized monoclonal antibody without detrimental effects on the patient’s glucose control especially in terms of HbA1c (glycated hemoglobin), time in glycemic range (TIR), and daily insulin needs.https://www.frontiersin.org/articles/10.3389/fimmu.2022.853561/fullchronic spontaneous urticariatype 1 diabetesomalizumabpediatricsglycemic |
| spellingShingle | Paolo Del Barba Federica Del Tedesco Federica Del Tedesco Giulio Frontino Giulio Frontino Maria Pia Guarneri Riccardo Bonfanti Riccardo Bonfanti Riccardo Bonfanti Graziano Barera Case Report: Safety and Efficacy of Omalizumab in a 13-Year-Old Patient With Chronic Spontaneous Urticaria and Type 1 Diabetes Frontiers in Immunology chronic spontaneous urticaria type 1 diabetes omalizumab pediatrics glycemic |
| title | Case Report: Safety and Efficacy of Omalizumab in a 13-Year-Old Patient With Chronic Spontaneous Urticaria and Type 1 Diabetes |
| title_full | Case Report: Safety and Efficacy of Omalizumab in a 13-Year-Old Patient With Chronic Spontaneous Urticaria and Type 1 Diabetes |
| title_fullStr | Case Report: Safety and Efficacy of Omalizumab in a 13-Year-Old Patient With Chronic Spontaneous Urticaria and Type 1 Diabetes |
| title_full_unstemmed | Case Report: Safety and Efficacy of Omalizumab in a 13-Year-Old Patient With Chronic Spontaneous Urticaria and Type 1 Diabetes |
| title_short | Case Report: Safety and Efficacy of Omalizumab in a 13-Year-Old Patient With Chronic Spontaneous Urticaria and Type 1 Diabetes |
| title_sort | case report safety and efficacy of omalizumab in a 13 year old patient with chronic spontaneous urticaria and type 1 diabetes |
| topic | chronic spontaneous urticaria type 1 diabetes omalizumab pediatrics glycemic |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.853561/full |
| work_keys_str_mv | AT paolodelbarba casereportsafetyandefficacyofomalizumabina13yearoldpatientwithchronicspontaneousurticariaandtype1diabetes AT federicadeltedesco casereportsafetyandefficacyofomalizumabina13yearoldpatientwithchronicspontaneousurticariaandtype1diabetes AT federicadeltedesco casereportsafetyandefficacyofomalizumabina13yearoldpatientwithchronicspontaneousurticariaandtype1diabetes AT giuliofrontino casereportsafetyandefficacyofomalizumabina13yearoldpatientwithchronicspontaneousurticariaandtype1diabetes AT giuliofrontino casereportsafetyandefficacyofomalizumabina13yearoldpatientwithchronicspontaneousurticariaandtype1diabetes AT mariapiaguarneri casereportsafetyandefficacyofomalizumabina13yearoldpatientwithchronicspontaneousurticariaandtype1diabetes AT riccardobonfanti casereportsafetyandefficacyofomalizumabina13yearoldpatientwithchronicspontaneousurticariaandtype1diabetes AT riccardobonfanti casereportsafetyandefficacyofomalizumabina13yearoldpatientwithchronicspontaneousurticariaandtype1diabetes AT riccardobonfanti casereportsafetyandefficacyofomalizumabina13yearoldpatientwithchronicspontaneousurticariaandtype1diabetes AT grazianobarera casereportsafetyandefficacyofomalizumabina13yearoldpatientwithchronicspontaneousurticariaandtype1diabetes |